PHARM Stock Overview
Pharmiva AB (publ) engages in the research and development of medical products in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Pharmiva AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.56 |
| 52 Week High | SEK 2.74 |
| 52 Week Low | SEK 0.56 |
| Beta | 1.56 |
| 11 Month Change | -39.52% |
| 3 Month Change | -31.03% |
| 1 Year Change | -61.11% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -94.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| PHARM | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | -20.0% | -5.5% | -2.4% |
| 1Y | -61.1% | 9.1% | 10.9% |
Return vs Industry: PHARM underperformed the Swedish Pharmaceuticals industry which returned 28.5% over the past year.
Return vs Market: PHARM underperformed the Swedish Market which returned 5.8% over the past year.
Price Volatility
| PHARM volatility | |
|---|---|
| PHARM Average Weekly Movement | 20.2% |
| Pharmaceuticals Industry Average Movement | 10.6% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in SE Market | 11.2% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: PHARM's share price has been volatile over the past 3 months.
Volatility Over Time: PHARM's weekly volatility has increased from 14% to 20% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 5 | Anna Linton | www.pharmiva.com |
Pharmiva AB (publ) engages in the research and development of medical products in Sweden. The company offers Vernivia, an over-the-counter vaginal mousse for the treatment of bacterial vaginosis. The company was incorporated in 2015 and is headquartered in Lund, Sweden.
Pharmiva AB (publ) Fundamentals Summary
| PHARM fundamental statistics | |
|---|---|
| Market cap | SEK 9.73m |
| Earnings (TTM) | -SEK 21.42m |
| Revenue (TTM) | SEK 4.26m |
2.3x
P/S Ratio-0.5x
P/E RatioIs PHARM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHARM income statement (TTM) | |
|---|---|
| Revenue | SEK 4.26m |
| Cost of Revenue | SEK 1.65m |
| Gross Profit | SEK 2.61m |
| Other Expenses | SEK 24.03m |
| Earnings | -SEK 21.42m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.23 |
| Gross Margin | 61.22% |
| Net Profit Margin | -502.51% |
| Debt/Equity Ratio | 0% |
How did PHARM perform over the long term?
See historical performance and comparison